Managed Access Program Supporting Patient Access to Tebentafusp

Learn more about:
Related Clinical Trial
Retrospective Register for Uveal Melanoma Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Adjuvant Melatonin for Uveal Melanoma Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Managed Access Program Supporting Patient Access to Tebentafusp Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

Official Title

A Cohort IND Expanded Access Program (EAP) for Tebentafusp for Treatment of HLA-A*02:01 Positive Patients With Metastatic Uveal Melanoma

Brief Summary

      This Expanded Access Program aims to:

        1. Provide access to tebentafusp for mUM patients.

        2. Provide access to tebentafusp for patients, who were on the control arm of the
           randomized controlled Phase II trial (IMCgp100-202) and were unable to crossover during
           the specified window.

        3. Ensure that patients, who are benefiting from tebentafusp treatment while participating
           in an ongoing Immunocore sponsored clinical study (e.g., IMCgp100-102 or IMCgp100-201),
           may continue tebentafusp treatment on this Programme once the ongoing trial has met all
           of its key primary and secondary objectives.

Study Type

Expanded Access


Uveal Melanoma




* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Eligibility Criteria

        Inclusion Criteria:


          1. Male or female patients age ≥ 18 years of age at the time of first dose

             Type of Participant and Disease Characteristics

          2. Histologically or cytologically confirmed metastatic UM or unresectable UM patients

          3. HLA-A*02:01 positive

          4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

             Informed Consent

          5. Ability to provide and understand informed consent prior to procedures [if required]


          6. Male and female participants of childbearing potential who are sexually active with a
             non-sterilized partner must agree to use highly effective methods of birth control
             from the trial screening date until 1 week after the final dose of the program
             intervention; cessation of birth control after this point shall be discussed with a
             responsible physician.

               1. Pregnant or lactating women are prohibited from enrolling on this program.

               2. Male participants are not allowed to donate sperm from the time of enrolment
                  until 3 months post- administration of program interventions.

        Exclusion Criteria:

        Disease Under Study and Prior Anticancer Therapy

          1. Presence of untreated or symptomatic central nervous system (CNS) metastases,
             leptomeningeal disease, or cord compression. NOTE: Participants with treated CNS
             lesions may enroll provided all of the following apply:

               1. Treated CNS lesions must be radiographically stable for ≥ 2 weeks after
                  intervention (surgery and/or radiation).

               2. Participants must be neurologically stable off systemic corticosteroids for at
                  least 2 weeks prior to first planned administration of tebentafusp.

          2. Receipt of anticancer therapy for the disease under study within the following times
             prior to the first planned dose of program intervention:

               1. Cellular therapies (e.g., T-cell therapies): 90 days.

               2. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)- targeted immunotherapies
                  (e.g., ipilimumab): 28 days

               3. All other immunotherapies, including PD-(L)1-targeted immunotherapies (e.g.,
                  atezolizumab, pembrolizumab): 21 days

               4. All other systemic therapies: 14 days

               5. Radiotherapy: 14 days (excepting palliative radiotherapy to a limited field
                  [e.g., for a focally painful tumor mass], which may be administered within 14
                  days provided there are no ongoing related Grade 2 or higher toxicities)

             Medical Conditions and Concomitant Medications

          3. Systemic treatment with steroids or any other immunosuppressive drug use within 2
             weeks of the planned first dose of program intervention, with the following

               1. Treatment for well-controlled and asymptomatic adrenal insufficiency is
                  permitted, but replacement dosing is limited to prednisone ≤ 12 mg daily or the

               2. Local steroid therapies (e.g., optic, ophthalmic, intra- articular, or inhaled
                  medications) are acceptable.

               3. Premedication for allergy to contrast reagent.

               4. Steroids for management of CNS metastases > 2 weeks prior to the planned first
                  dose of program intervention.

          4. Any relevant medical condition, which in the opinion of the treating physician, would
             prevent the participant enrolling into the Program due to concerns related to safety,
             compliance with procedures, or interpretation of program results.

          5. Chronic viral infections as indicated below. NOTE: Testing for hepatitis C virus (HCV)
             status prior to enrollment is not necessary unless clinically indicated.

               1. Known history of human immunodeficiency virus (HIV) infection.

               2. Known HBV infection, unless on stable anti-viral therapy for > 4 weeks prior to
                  the planned first dose of program intervention and viral load confirmed as
                  undetectable during Screening.

               3. Known HCV infection, unless the participant has received curative treatment and
                  viral load was confirmed as undetectable during Screening.

             Diagnostic Assessments

          6. Participant with an out-of-range Screening laboratory values defined as shown below.
             NOTE: Hematology evaluations must be performed ≥ 7 days from any blood or blood
             product transfusion and ≥ 14 days from any dose of hematologic growth factor.

               1. Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 30

               2. Total bilirubin > 1.5 × ULN, except for patients with Gilbert's syndrome who are
                  excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN

               3. Alanine aminotransferase > 5 × ULN

               4. Aspartate aminotransferase > 5 × ULN

               5. Platelet count < 50 × 109/L

               6. Hemoglobin < 8 g/dL

          7. Clinically significant cardiac disease or impaired cardiac function, including any of
             the following:

               1. Congestive heart failure (New York Heart Association Class ≥ 3)

               2. Uncontrolled hypertension defined as systolic blood pressure [BP] > 160 mmHg or
                  diastolic BP > 110 mmHg with the following requirements:

               1. If initial measurement is elevated, additional assessments should be taken where
                  each assessment is the mean value of 3 measurements taken at least 5 minutes

               2. Eligibility is based on the average of at least 2 assessments taken at least 1
                  hour apart.

               3. Acute myocardial infarction or unstable angina pectoris < 6 months prior to the
                  planned first dose of program intervention




18 Years - N/A


, 1-844-IMMUNO-1, [email protected]

Administrative Informations



Organization ID

IMCgp100-402 EA

Responsible Party


Study Sponsor

Immunocore Ltd


 Clinigen, Inc.

Study Sponsor

, , 

Verification Date

January 2022